Indications for Methyldopa/Hydrochlorothiazide Tablets:
Titrate individual components. Initially one 250mg/15mg tab 2–3 times daily or one 250mg/25mg tab 2 times daily. Max 3g/day methyldopa and 50mg/day HCTZ.
Methyldopa/Hydrochlorothiazide Tablets Contraindications:
Active hepatic disease. Anuria. Sulfonamide allergy. History of methyldopa-associated liver dysfunction. Concomitant MAOIs.
Methyldopa/Hydrochlorothiazide Tablets Warnings/Precautions:
History of hepatic dysfunction. Pheochromocytoma. Severe cerebrovascular or renal disease. SLE. Gout. Diabetes. Asthma. Edema. Dialysis. Postsympathectomy. Monitor blood, liver function, blood lipids, and electrolytes. Surgery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Methyldopa/Hydrochlorothiazide Tablets Classification:
Central alpha agonist + diuretic.
Methyldopa/Hydrochlorothiazide Tablets Interactions:
MAOIs (see Contraindications). Alcohol, CNS depressants may increase orthostatic hypotension. May increase toxicity of diazoxide, digitalis and lithium. May antagonize oral hypoglycemics. Antagonized by NSAIDs, iron. May interfere with parathyroid tests.
Hemolytic anemia, fever, jaundice, hepatic necrosis, granulocytopenia, fluid or electrolyte imbalance, blurred vision, sedation, headache, asthenia, orthostatic hypotension, bradycardia, GI upset, rash, nasal congestion, hyperprolactinemia, arthralgia, positive Coomb's test.
Formerly known under the brand name Aldoril.